文献速递主动脉疾病内脏/肾动脉与血管畸形

开窗腔内修复术中用于肾动脉和内脏动脉的新型预装载系统

New Preloaded System for Renal and Visceral Arteries in Fenestrated Endografting.
PubMed 文献 · J Endovasc Ther · 2023-06-13

前瞻性单中心观察性研究纳入74例接受新型预装载系统开窗腔内修复术的近肾/肾旁腹主动脉瘤和胸腹主动脉瘤患者,技术成功率为96%,预装载系统相关技术成功率为99%,30天/院内死亡率为1.3%,随访中位14个月,估计3年生存率为91%。

要点

  • 新型预装载系统开窗腔内修复术技术成功率为96%(71/74),预装载系统相关技术成功率为99%(73/74)。
  • 30天/院内死亡率为1.3%(1/74),死因为经皮闭合系统破损导致大出血后多器官衰竭。
  • 估计3年生存率为91%,无动脉瘤相关死亡,估计3年免于再干预率为85%,免于靶内脏血管不稳定性为92%。

核心结论

  • 新型预装载系统开窗腔内修复术在存在不良髂动脉入路或需保证快速盆腔/下肢再灌注时,是治疗近肾/肾旁腹主动脉瘤和胸腹主动脉瘤的安全有效选择,技术成功率和早中期临床结果令人满意。

研究设计与样本

  • 前瞻性(NCT05224219)单中心观察性研究,纳入2019年至2022年7月期间接受新型预装载系统开窗腔内修复术的近肾/肾旁腹主动脉瘤和胸腹主动脉瘤患者,共74例(占157例开窗/分支腔内修复术的47%),其中近肾/肾旁腹主动脉瘤48例(65%),胸腹主动脉瘤26例(35%)。

主要发现

  • 共292条靶内脏血管由289个开窗和3个分支覆盖,289个开窗中188个(65%)为预装载。
  • 新型预装载系统开窗腔内修复术配置为「下方」和「下方至上方」者分别为28例(38%)和46例(62%)。
  • 技术成功率为96%(71/74),预装载系统相关技术成功率为99%(73/74),完成血管造影时靶内脏血管通畅率为99%(290/292)。
  • 失败包括2条肾动脉丢失和1例经皮闭合系统破损导致大出血,后者术后发生多器官衰竭并于术后第5天死亡,为唯一的30天/院内死亡(1.3%)。
  • 1例(1.3%)近肾腹主动脉瘤且术前双侧髂内动脉闭塞的患者发生脊髓缺血;中位随访14个月(IQR:8),估计3年生存率为91%,随访期间无动脉瘤相关死亡,估计3年免于再干预率和免于靶内脏血管不稳定性分别为85%和92%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM/BACKGROUND: The New Preloaded System (NPS) for renal/visceral arteries (TVVs) is an emerging technology in fenestrated endografting (FEVAR) that allows TVVs cannulation and stenting through the same access of the endograft main body. However, only few preliminary experiences are currently available in the literature. The aim of this study is to report the outcomes of NPS-FEVAR in juxta/para-renal (J/P-AAAs) and thoracoabdominal (TAAAs) aneurysms repair. METHODS: This is a prospective (NCT05224219), single-center/observational study of patients submitted to NPS-FEVAR for J/PAAAs and TAAAs between 2019 and 2022 (July). Definitions and outcomes were evaluated according to the current SVS-reporting standard. Technical success (TS) and TS preloaded related, spinal cord ischemia (SCI), and 30-day mortality were assessed as early endpoints. Survival, freedom from reinterventions (FFRs), and freedom from TTVs-instability (FFTVVs-instability) were analyzed during follow-up. RESULTS: Among 157 F/B-EVAR cases, 74 (47%) NPS-FEVAR were planned and enrolled in the study [48 (65%) J/P-AAAs; 26 (35%) TAAAs]. The main indication for NPS-FEVAR was the presence of a hostile iliac axis (54%-73%) or the necessity of expeditious pelvic/lower-limb reperfusion for SCI prevention in TAAAs (20%-27%). Overall, 292 TVVs were accommodated by 289 fenestrations and 3 branches; 188 of 289 (65%) fenestrations were preloaded. NPS-FEVAR configuration was from "below" and "from below to above" in 28 (38%) and 46 (62%) cases, respectively. TS and TS preloaded system-related was 96% (71/74) and 99% (73/74), respectively. Target visceral vessels patency at the completion angiography was 99% (290/292). Failures were 2 renal arteries loss and 1 massive bleeding from a percutaneous closure system breakage. The latter patient developed postoperative multiorgans failure and died on the fifth postoperative day, causing only 30-day/in-hospital mortality (1.3%). One (1.3%) patient with a JAAA and preoperative bilateral occlusion of the hypogastric arteries suffered SCI. The median follow-up was 14 (IQR: 8) months. The estimated 3-year survival was 91% with no aneurysm-related mortality during follow-up. The estimated 3-year FFR and FFTVVs-instability were 85 and 92%, respectively. CONCLUSION: New preloaded system FEVAR is a safe and effective option in the treatment of J/PAAAs and TAAAs in the presence of hostile iliac access or to guarantee an expeditious pelvic/lower limb reperfusion, leading to satisfactory results in terms of TS, early and mid-term clinical outcomes.Clinical ImpactNew preloaded system for fenestrated and branched endografting allows to increase the feasibility of the advanced endovascular aortic repair in challenging iliac access, thoracoabdominal aneurysm repair and reduce difficulties in target visceral vessels cannulation.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Gallitto E, Faggioli G, Spath P, et al. New Preloaded System for Renal and Visceral Arteries in Fenestrated Endografting. J Endovasc Ther. 2023. PMID: 37309170. doi:10.1177/15266028231179868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。